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Sim1 haploinsufficiency in mice induces hyperphagic obesity and developmental abnormalities of the brain. 
In humans, abnormalities in chromosome 6q16, a region that includes SIM1, were reported in obese children 
with a Prader-Willi–like syndrome; however, SIM1 involvement in obesity has never been conclusively dem-
onstrated. Here, SIM1 was sequenced in 44 children with Prader-Willi–like syndrome features, 198 children 
with severe early-onset obesity, 568 morbidly obese adults, and 383 controls. We identified 4 rare variants 
(p.I128T, p.Q152E, p.R581G, and p.T714A) in 4 children with Prader-Willi–like syndrome features (including 
severe obesity) and 4 other rare variants (p.T46R, p.E62K, p.H323Y, and p.D740H) in 7 morbidly obese adults. 
By assessing the carriers’ relatives, we found a significant contribution of SIM1 rare variants to intra-family 
risk for obesity. We then assessed functional effects of the 8 substitutions on SIM1 transcriptional activities in 
stable cell lines using luciferase gene reporter assays. Three mutations showed strong loss-of-function effects 
(p.T46R, p.H323Y, and p.T714A) and were associated with high intra-family risk for obesity, while the vari-
ants with mild or no effects on SIM1 activity were not associated with obesity within families. Our genetic and 
functional studies demonstrate a firm link between SIM1 loss of function and severe obesity associated with, 
or independent of, Prader-Willi–like features.
Introduction
The basic helix-loop-helix–PER-ARNT-SIM (bHLH-PAS) tran-
scription factor single-minded 1 (SIM1) plays a key role in 
neuronal differentiation within the paraventricular nucleus of 
the hypothalamus, which is critical for food intake regulation 
(1). Sim1-haploinsufficient mice display hypodevelopment of the 
paraventricular nucleus of the hypothalamus and are hyperphagic, 
obese, and highly sensitive to diet-induced obesity, whereas Sim1 
overexpression in mice leads to a decrease in food intake (2–4). 
In humans, several deletions in the chromosome 6q16, the region 
that includes SIM1, have been identified in obese patients pre-
senting with a Prader-Willi–like (PWL-like) syndrome (5), which 
is characterized in early infancy by global developmental delay, 
hypotonia, and feeding difficulties and later in life by hyperphagia, 
obesity, and facial dysmorphisms (6). The 4.1-Mb critical region 
for PWL syndrome includes SIM1 but also 11 other genes or gene 
predictions, and the specific role of SIM1 haploinsufficiency in the 
development of PWL syndrome has not definitively been estab-
lished (6). Nonetheless, a de novo balanced translocation disrupt-
ing SIM1 has been described in a patient presenting with severe 
obesity but no other clinical features suggestive of a PWL syn-
drome (7). Another study reported 6 rare non-synonymous SIM1 
mutations in extremely obese patients only, but no functional 
analyses were performed (8).
In the present study, we aimed to assess the contribution of rare 
mutations in SIM1 to monogenic and syndromic forms of obesity. 
Coding regions of SIM1 were sequenced in 44 children present-
ing with PWL syndrome features, 198 children with severe early-
onset obesity, 568 morbidly obese adults, and 383 normal-weight 
controls. Subsequently, we functionally characterized the effects 
of the mutations on SIM1 activity and analyzed phenotypes in 
SIM1-deficient patients.
Results and Discussion
By focusing on rare coding variants only (minor allele frequency 
[MAF] <1%), we identified 4 substitutions (p.I128T, p.Q152E, 
p.R581G, and p.T714A; Figure 1) in 4 children presenting with 
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clinical features of PWL syndrome, including severe obesity that 
started between 1 and 2 years of age (Table 1 and Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI68035DS1), and 4 other substitutions (p.T46R, 
p.E62K, p.H323Y, and p.D740H; Figure 1) in 7 morbidly obese 
adults (Table 1 and Supplemental Table 2).
With regard to the obese child SIM1 mutant carriers presenting 
with PWL syndrome (Supplemental Table 1 and Supplemental 
Figure 1), the girl carrying the p.I128T variant received the sub-
stitution from her normal-weight father. The mother of the girl 
carrying the p.Q152E variant did not carry this substitution; the 
father’s DNA and phenotypes were not available. The girl carrying 
the p.R581G variant was an adopted child. In contrast, we were 
able to investigate the family of the boy carrying the p.T714A vari-
ant. His 3 siblings, his mother, and a maternal aunt also carried 
this substitution. The mother and her 4 children were severely 
obese and presented at least one other clinical feature associated 
with PWL syndrome, while the aunt was only overweight and with-
out clinical abnormalities (Supplemental Table 3).
Among the morbidly obese adult SIM1 mutant carriers (Supple-
mental Table 2 and Supplemental Figure 2), 4 unrelated patients 
carried the same p.T46R variant. In the first mutated participant, 
the p.T46R variant had arisen de novo. In the second mutated 
participant, the p.T46R variant had been inherited from his obese 
mother. Furthermore, this participant had an obese sister who also 
carried the p.T46R variant. Although parental DNA samples were 
Figure 1
Location of the 8 SIM1 rare substitutions. At the top are shown the substitution locations in exons. In the middle are shown the substitution loca-
tions in protein domains (only substitutions located in specific domains are reported). At the bottom are shown the substitution locations in the 
SIM1 766-amino-acid protein.
Table 1
Genetic and functional description of the 8 SIM1 rare substitutions
Variant p.T46R p.E62K p.I128T p.Q152E p.H323Y p.R581G p.T714A p.D740H
Codon change ACG>AGG GAG>AAG ATT>ACT CAG>GAG CAC>TAC AGA>GGA ACT>GCT GAT>CAT
dbSNP135 – rs201038781 rs138546433 rs140908824 – – – –
MAF (in European – NA 0.06% 0.01% – – – – 
 Americans)
No. carriers (probands and their relatives)
 PWL syndrome 0 0 1 1 0 1 5 0
 Obesity 7 1 0 0 2 0 0 1
 Overweight 0 0 0 0 0 0 1 0
 Normal weight 0 0 1 0 0 0 0 0
In silico functional prediction
 Polyphen-2 Probably  Probably   Possibly  Benign Probably  Possibly  Benign Probably
 damaging damaging damaging  damaging damaging  damaging
 Sift Deleterious Deleterious  Deleterious  Tolerated Tolerated Deleterious Tolerated  Tolerated
 SNAP Non neutral Neutral Neutral Neutral Non neutral Non neutral Neutral Non Neutral
 Pmut Pathological Pathological Pathological Neutral Neutral Pathological Neutral Pathological
 Align GVGD C15 C0 C25 C0 C0 C0 C0 C0
 TotalA 5 3 4 0 2 4 0 3
Functional effect according  2 1 1 1 2 0 2 1
to the present investigationB
AThe total risk score (0 = lowest risk → 5 = highest risk) is the sum of each score calculated per software (see Supplemental Methods): 0 if Polyphen-2 = 
“Benign,” Sift = “Tolerated,” SNAP = “Neural,” Pmut = “Neutral,” Align GVGD = “C0”; 1 if different than “benign,” “tolerant,” “neutral,” or “C0.” B0 = no effect;  
1 = mild effect on SIM1 activity with ARNT or ARNT2; 2 = strong effect on SIM1 activity with ARNT and ARNT2. MAF is according to the NHLBI Exome  
Project. NA, not available.
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not available for the third p.T46R-carrying participant, her obese 
son carried the substitution, while her normal-weight sister and 
normal-weight daughter did not. The family of the fourth p.T46R-
carrying participant was not available. The patient carrying the 
p.E62K variant had a normal-weight mother and 2 normal-weight 
daughters, none of whom carried the substitution. His severely 
obese father has died, and no DNA was available. The carrier of 
the p.H323Y variant had a morbidly obese sister who was also a 
p.H323Y carrier, while both parents had died. No DNA was avail-
able from relatives of the p.D740H carrier.
In summary, we identified 21 (adults and children) carriers of a 
rare heterozygous SIM1 variant (11 probands and 10 of their rela-
tives) and 16 non-carrier relatives, and we found a strong contri-
bution of SIM1 rare variants to intra-family risk for obesity (odds 
ratio[95% confidence interval]: OR = 20.9[3.5–126.5]; P = 9.3 × 10–4).
Of note, 3 of the 8 rare variants have been listed in the Single 
Nucleotide Polymorphism database (dbSNP 137) — p.E62K/
rs201038781, p.I128T/rs138546433, and p.Q152E/rs140908824 
— but are very rare in the general population, according to the 
NHLBI Exome Project and the 1000 Genomes Project (MAF 
<0.1%). When we sequenced 383 normal-weight controls, we found 
a single carrier of the p.I128T variant (in the heterozygous state). 
A previous study reported that p.I128T did not cosegregate with 
either obesity or overweight phenotype in a family of European 
descent (9). Therefore, this variant is unlikely to have a signifi-
cant effect on obesity or PWL-related clinical features. We then 
genotyped 2,896 normal-weight individuals but did not find any 
carriers of the substitutions p.T46R, p.E62K, p.Q152E, p.H323Y, 
p.R581G, p.T714A, or p.D740H.
Subsequently, we aimed to functionally assess the 8 rare substi-
tutions. Using five types of in silico prediction software, we found 
that the mutation with the highest risk score of damaging effect 
was p.T46R, while the substitutions with the lowest risk score 
were p.Q152E and p.T714A (Table 1). One of the aryl hydrocar-
bon receptor nuclear translocators, either ARNT or ARNT2, is 
required as a dimerization partner for SIM1 to function as a tran-
scription factor, with mouse knockout studies suggesting that 
ARNT2 is the in vivo partner in the hypothalamus (10, 11). We 
constructed a homology model to estimate structural features of 
the SIM1:ARNT2 dimer at the bHLH and PASA domains, which 
was based upon the crystal structure for the N-terminal half of 
the CLOCK:BMAL1 dimer (12). We found that the N-terminal 
amino acids (T46, E62, I128, and Q152) likely lie on the surface 
of the protein (Figure 2A). E62, I128, and Q152 amino acids were 
located in unstructured loops (Figure 2, B and C); thus, their pos-
sible contributions to perturbations of SIM1 structure could not 
be estimated. However, T46 lay in the middle of a helix that was in 
close proximity to a helix of ARNT2 (Figure 2B); thus, the larger 
arginine residue may critically perturb the dimerization interface.
We then assessed the functional effects of the 8 substitu-
tions on the transcriptional properties of the SIM1:ARNT and 
SIM1:ARNT2 dimers in vitro using luciferase gene reporter assays 
in human 293 Flp-In T-Rex stable cell lines expressing the WT 
protein or one of the 8 SIM1 mutants (Figure 3, A and B). Impor-
tantly, with this system, only 1 copy of the mutated (or WT) SIM1 
is integrated at a specific and predefined insertion site in the cell 
genome. This renders activity levels independent of the number 
of inserted copies and the insertion site, and allowed an accurate 
comparison of the mutants’ activities. We found a strong loss-
of-function effect of p.T46R, p.H323Y, and p.T714A mutations 
on SIM1 transcriptional activity with both ARNT and ARNT2 
(P < 0.001; Figure 3C). These mutations were located in the bHLH, 
PASB, and C-terminal domains, respectively (Figure 1). The 3 
mutations were identified in morbidly obese adults (n = 9 carriers 
of p.T46R or p.H323Y), in 1 overweight adult (carrier of p.T714A), 
and in severely obese subjects with PWL syndrome (n = 4 carriers of 
p.T714A). Together, these loss-of-function mutations were associ-
ated with a strong intra-family risk for obesity (OR = 28.0[2.7–295.7]; 
P = 5.6 × 10–3). The p.I128T and p.Q152E variants, which were 
identified either in normal-weight participants (n = 2 carriers of 
p.I128T) or in severely obese subjects with PWL syndrome (n = 2 
carriers of p.I128T or p.Q152E), had a milder loss-of-function 
effect on SIM1 activity with ARNT or ARNT2 (Figure 3C). Two 
substitutions (p.E62K and p.D740H) which were identified in 2 
morbidly obese participants, had a gain-of-function effect on SIM1 
activity with ARNT only (Figure 3C). We did not detect any effect 
of p.R581G on SIM1 activity (Figure 3C), which was identified in 
a severely obese participant with PWL syndrome. Together, the 
Figure 2
Homology model of the SIM1:ARNT2 heterodimer. SIM1 is shown in yellow and ARNT2 in green. (A) Surface representation of SIM1, with 
amino acids that harbor variants shown in red. (B and C) Ribbons diagram of the SIM1:ARNT2 heterodimer, with amino acids that harbor 
variants depicted in pink.
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rare variants with mild or no effects on SIM1 activity were not sig-
nificantly associated with obesity within families (OR = 7.5[0.5–122.7]; 
P = 0.158). When we compared our functional data with the in 
silico predictions, only 62.5% concordance was found.
Our genetic and functional studies, together with the findings 
of Ramachandrappa et al. (13), convincingly demonstrate a link 
between SIM1 loss of function and severe to morbid obesity that 
may also be associated with PWL-related clinical features includ-
ing developmental delay (or intellectual disability) and facial dys-
morphism. The observed effects of SIM1 loss-of-function muta-
tions on both development and body weight regulation are in line 
with the key role of SIM1 in development of the paraventricular 
nucleus of the hypothalamus (1). Importantly, the necdin protein 
(NDN), which is believed to be involved in the Prader-Willi syn-
drome (14), regulates the activity of the SIM1:ARNT2 dimer (15), 
reinforcing the putative role of SIM1 in the PWL syndrome.
SIM1 non-synonymous mutations were present in numerous 
patients with severe obesity associated with, or independent of, 
PWL-related clinical features. Some mutations, such as p.T46R, 
dramatically reduced SIM1 activity on a reporter gene and were 
only found in obese individuals, suggesting that loss-of-function 
SIM1 mutants may underpin a monogenic form of obesity. How-
ever, some substitutions with marked loss-of-function effect (e.g., 
p.T714A) did co-segregate with overweight/obesity but were not 
always associated with severe obesity or PWL syndrome. Moreover, 
the p.I128T variant, which caused mild loss of SIM1 function, was 
unlikely to contribute to obesity. Therefore, mutation of SIM1 is 
not always responsible for a fully penetrant form of obesity. Simi-
lar features have been repeatedly found in MC4R loss-of function 
mutation carriers, where a permissive role of the environment on 
disease expression has been suggested (16, 17). The degree of pen-
etrance is expected to be determined by the severity of loss of func-
tion of a particular mutant in combination with environment and 
genetic background. In obese patients presenting with the clinical 
features associated with Prader-Willi syndrome, if chromosomes 
15q11 and 6q16 are found not to contain abnormalities, then 
SIM1 sequencing and subsequent molecular characterization 
should be performed, in order to demonstrate the presence of 
causative loss-of-function mutations.
Methods
Further information is available in Supplemental Methods.
Statistics. For the genetic study, effects of mutation on obesity risk were 
calculated through univariate logistic regression models using SPSS 14.0. 
For the functional analysis, univariate ANOVA was performed on the log 
values generated for each mutant with reference to WT using SPSS 17.0. 
Separate analyses were performed for ARNT- and ARNT2-transfected cells. 
A P value less than 0.05 was considered significant.
Study approval. The study protocol was approved by the ethics commit-
tees of Lille II University, the University of Antwerp, the Canton of Zurich, 
and the University of Paris-Sud and the Institutional Review Board of the 
University of Florida, and study participants signed informed consent 
agreements. For children younger than 18 years, oral consent was obtained, 
and parents provided written informed consent.
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